TIVC.NASDAQTivic Health Systems, INC
10-Q: Tivic Health Systems Reports Q1 2025 Financial Results, Focuses on Biopharma and Bioelectronic Pipeline
Sentiment:
Quarterly Report
Tivic Health Systems reports a decrease in revenue for Q1 2025, shifting focus to biopharma and bioelectronic development with strategic acquisitions and financing activities.
Capital raiseThe company entered into an Equity Purchase Agreement with Mast Hill Fund, L.P. for up to $25 million.The company entered into a Securities Purchase Agreement with an investor for up to $8.4 million through the sale of Series B Non-Voting Convertible Preferred Stock and warrants.
Worse than expectedRevenue decreased significantly by 79% compared to the same period last year.Cash and cash equivalents decreased to $669 thousand.The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
Summary
- Tivic Health Systems, Inc. reported its financial results for the quarter ended March 31, 2025.
- Revenue decreased by 79% to $70 thousand, primarily due to reduced advertising spend.
- The company incurred a net loss of $1.502 million, similar to the $1.481 million loss in the same period of 2024.
- Research and development expenses increased to $335 thousand, while sales and marketing expenses decreased to $179 thousand.
- General and administrative expenses increased to $1.042 million.
- The company's cash and cash equivalents decreased to $669 thousand.
- Tivic Health is focusing on developing its biopharma and bioelectronic pipeline.
- The company acquired an exclusive license for Entolimod from Statera Biopharma, Inc. and exercised an option to license it for neutropenia.
- Tivic Health entered into an Equity Purchase Agreement with Mast Hill Fund, L.P. for up to $25 million.
- The company implemented a 1-for-17 reverse stock split on March 7, 2025.
- Subsequent to the end of the quarter, the Company sold a total of 172,700 shares of common stock pursuant to the Distribution Agreement for gross proceeds of $1.8 million and net proceeds of $1.7 million after $53 thousand of commissions paid by the Company to Maxim.
- The company entered into a Securities Purchase Agreement with an investor for up to $8.4 million through the sale of Series B Non-Voting Convertible Preferred Stock and warrants.
- The company entered into a Statement of Work with Scorpius BioManufacturing, Inc. for manufacturing services related to Entolimod, with an estimated investment of $4.1 million.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While the company is making strategic moves to expand its pipeline and secure financing, the declining revenue and going concern uncertainty raise concerns. The sentiment is neutral, reflecting both positive developments and significant challenges.
Positives
- The company acquired an exclusive license for Entolimod, expanding its biopharma pipeline.
- Tivic Health exercised an option to license Entolimod for the treatment of neutropenia, further diversifying its therapeutic focus.
- The company secured an Equity Purchase Agreement with Mast Hill Fund, L.P. for up to $25 million, providing potential access to capital.
- Tivic Health entered into a Securities Purchase Agreement with an investor for up to $8.4 million through the sale of Series B Non-Voting Convertible Preferred Stock and warrants.
- The company entered into a Statement of Work with Scorpius BioManufacturing, Inc. for manufacturing services related to Entolimod, with an estimated investment of $4.1 million.
Negatives
- Revenue decreased significantly by 79% to $70 thousand.
- The company continues to incur net losses, with a loss of $1.502 million for the quarter.
- Cash and cash equivalents decreased to $669 thousand.
- The company's auditors have raised substantial doubt about the company's ability to continue as a going concern.
Risks
- The company's ability to continue as a going concern is uncertain due to recurring losses and limited cash reserves.
- The company's success depends on the development and commercialization of new product candidates, which is subject to regulatory approval and market acceptance.
- The company may need to raise additional capital to fund its operations, and there is no guarantee that such financing will be available on commercially acceptable terms.
- Global supply chain shortages and economic uncertainty could negatively affect the company's operations.
- The company is subject to risks associated with operating as a public company, including increased costs and regulatory compliance requirements.
Future Outlook
The company expects to incur substantial additional operating losses for the foreseeable future to expand its markets, conduct pre-clinical and clinical trials, complete development or acquisition of new product lines, obtain regulatory approvals, launch and commercialize its products and continue research and development programs.
Industry Context
Tivic Health's shift towards biopharma and bioelectronic development reflects a broader trend in the healthcare industry towards innovative therapies and non-invasive treatments. The acquisition of Entolimod and focus on vagus nerve stimulation positions the company to capitalize on emerging opportunities in immunotherapeutics and neuromodulation.
Comparison to Industry Standards
- It is difficult to compare Tivic Health directly to industry standards due to its unique combination of bioelectronic and biopharmaceutical assets.
- Comparable companies in the bioelectronic space include electroCore, Inc. and NeuroMetrix, Inc., which focus on neuromodulation therapies.
- In the biopharmaceutical space, companies like Statera Biopharma, Inc. (from which Tivic licensed Entolimod) are developing immunotherapeutics.
- However, Tivic's financial performance and market capitalization are significantly smaller than these established players, reflecting its early stage of development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer of Tivic and President, Tivic Biopharma | NA | Michael Handley | February 18, 2025 | To lead the establishment of a biopharmaceutical capability within Tivic. |
Stakeholder Impact
- Shareholders face potential dilution from equity offerings and the risk of declining stock value due to financial challenges.
- Employees may experience uncertainty due to cost-cutting measures and the company's focus on new therapeutic areas.
- Customers may see changes in the availability and marketing of ClearUP as the company shifts its focus.
- Suppliers and creditors may face increased scrutiny and potential delays in payments due to the company's financial situation.
Next Steps
- Advance the development of Entolimod and Entolasta through manufacturing process validation and regulatory submissions.
- Continue research and development efforts in vagus nerve stimulation.
- Seek strategic partnerships and collaborations to support clinical development and commercialization.
- Explore alternative monetization strategies for ClearUP.
- Obtain stockholder approval for the conversion of Series A Preferred Stock and the issuance of additional shares under the Mast Hill Purchase Agreement.
Key Dates
| Date | Description |
|---|---|
| September 22, 2016 | Tivic Health Systems, Inc. was incorporated in California. |
| January 2019 | FDA provided clearance to ClearUP product under a 510(k) with clinical data as an allergy treatment. |
| March 2021 | FDA granted ClearUP a subsequent De Novo clearance, which expanded ClearUPs label. |
| June 2021 | The Company was reincorporated as a Delaware corporation. |
| November 10, 2021 | The 2017 Equity Incentive Plan terminated and was replaced by the 2021 Plan. |
| May 13, 2024 | The Company sold 277,059 shares of its common stock, together with Series A warrants and Series B warrants, to certain investors in a registered public offering. |
| June 28, 2024 | Received a notification letter from Nasdaq that the Company was not in compliance with the minimum bid price requirement. |
| August 9, 2024 | The Company adopted its Amended and Restated 2021 Equity Incentive Plan. |
| September 13, 2024 | The Company entered into an Equity Distribution Agreement with Maxim Group LLC. |
| December 27, 2024 | Received an additional letter from Nasdaq stating that it had not regained compliance with the Minimum Bid Price Requirement. |
| February 11, 2025 | The Company entered into an exclusive license agreement with Statera Biopharma, Inc. |
| March 6, 2025 | Received a letter from the Panel granting its request for continued listing on the Nasdaq Capital Market, provided that the Company implemented a reverse stock split of its common stock on March 7, 2025 and demonstrated compliance with all such continued listing requirements for the Nasdaq Capital Market as of March 20, 2025. |
| March 7, 2025 | The Company implemented a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, at a ratio of 1-for-17. |
| March 18, 2025 | The Company entered into an Equity Purchase Agreement with Mast Hill Fund, L.P. |
| March 28, 2025 | The Company notified Statera of its election to exercise its Exclusive Option to acquire the exclusive worldwide license to the neutropenia indication for Entolimod under the License Agreement. |
| March 31, 2025 | The Company issued $500 thousand shares of Company stock, consisting of an aggregate of 55,704 shares of common stock and approximately 131 shares of Series A Preferred Stock. |
| April 4, 2025 | Received a letter from Nasdaq confirming that the Company has regained compliance with the Minimum Bid Price Requirement. |
| April 29, 2025 | The Company entered into a Securities Purchase Agreement with an investor for up to $8.4 million through the sale of Series B Non-Voting Convertible Preferred Stock and warrants. |
| May 9, 2025 | The Company entered into a Statement of Work with Scorpius BioManufacturing, Inc. |
Keywords
Entolimod, Tivic Health, biopharma, bioelectronic, financial results, reverse stock split, license agreement, Equity Purchase Agreement, manufacturing, neutropenia, Acute Radiation Syndrome, ClearUP
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.